上海海利生物技术股份有限公司控股子公司收购口腔连锁公司股权进展公告详细解读

要点概述

• 控股子公司陕西瑞盛生物科技有限公司已完成对扬州及常州七家口腔连锁公司各51%股权的收购手续，股权转让总金额为人民币6,120万元。
• 本次收购涉及的七家公司工商变更登记手续已全部完成，标志着收购交易实质性落地，为公司在口腔医疗服务领域的扩张提供了坚实基础。
• 后续整合工作存在不确定性风险，公司将持续披露相关进展，提醒投资者注意相关风险。

详细内容

上海海利生物技术股份有限公司（证券代码：603718，证券简称：*ST海利）于2026年1月1日召开第五届董事会第十八次会议，并审议通过了《关于控股子公司收购扬州、常州七家口腔连锁公司股权的议案》。此次交易方案为控股子公司陕西瑞盛生物科技有限公司（简称“瑞盛生物”）以自有资金收购以下七家口腔连锁公司各51%的股权：

• 扬州金铂利口腔医院有限公司
• 扬州金铂利口腔门诊有限公司
• 仪征市金铂利市口口腔门诊有限公司
• 常州武进金铂利口腔门诊部有限公司
• 常州天宁龙洋金铂利口腔门诊部有限公司
• 溧阳金铂利口腔门诊部有限公司
• 溧阳溧城金铂利口腔门诊部有限公司

上述七家公司51%股权的收购总金额为6,120万元人民币。
2026年4月15日，公司召开董事会第十九次会议，审议并通过了《关于调整控股子公司收购常州两家口腔连锁公司股权相关价款支付安排的议案》，涉及溧阳金铂利口腔门诊部有限公司和溧阳溧城金铂利口腔门诊部有限公司的股权价款支付安排调整。

工商变更进展

近日，溧阳金铂利口腔门诊部有限公司和溧阳溧城金铂利口腔门诊部有限公司已完成股权转让相关的工商变更登记，并领取新营业执照。主要信息如下：

截至本公告披露日，涉及的七家公司工商变更手续已全部完成。值得注意的是，后续整合工作仍存在不确定性风险，公司将根据后续进展及时披露信息。

对投资者的影响及潜在利好

• 此次收购完成标志着上海海利生物技术股份有限公司在医疗服务细分领域——口腔连锁行业的布局落地，有望增强公司在医疗大健康赛道的业务竞争力和盈利能力。
• 6,120万元的收购总金额涉及重大资产运作，可能对公司未来的财务状况和经营成果产生重要影响。
• 工商变更手续全部完成显示交易基本落地，短期内有望提升市场对公司转型和扩张能力的认知，有一定的股价催化效应。
• 需要警惕后续整合是否顺利，若整合不达预期，可能对业绩及市场信心带来负面影响。

风险提示

• 后续整合存不确定性，公司将持续披露进展，投资者需关注相关风险。

免责声明：本文仅为基于公司公告的详细解读，不构成任何投资建议或买卖依据。投资者应结合自身实际，注意投资风险。

English Version

Detailed Update on the Progress of Shanghai Hile Bio’s Subsidiary Acquiring Dental Chain Company Equity

Key Highlights

• The subsidiary, Shaanxi Ruisheng Biotech, has completed the acquisition of 51% equity in seven dental chain companies in Yangzhou and Changzhou, with a total transaction amount of RMB 61.2 million.
• All business registration changes for the seven companies have been completed, marking the substantial completion of the acquisition and laying a solid foundation for the company’s expansion in the dental medical service sector.
• There are still uncertainties regarding the subsequent integration, and the company will continue to disclose progress, reminding investors of related risks.

Details

Shanghai Hile Bio-Tech Co., Ltd. (Stock Code: 603718, Stock Name: *ST Hile) approved the acquisition plan at its 18th board meeting on January 1, 2026. The plan involves its subsidiary, Shaanxi Ruisheng Biotech, using its own funds to acquire 51% equity in the following seven dental chain companies:

• Yangzhou Jinboli Dental Hospital Co., Ltd.
• Yangzhou Jinboli Dental Outpatient Co., Ltd.
• Yizheng Jinbolishi Dental Outpatient Co., Ltd.
• Changzhou Wujin Jinboli Dental Outpatient Co., Ltd.
• Changzhou Tianning Longyang Jinboli Dental Outpatient Co., Ltd.
• Liyang Jinboli Dental Outpatient Co., Ltd.
• Liyang Licheng Jinboli Dental Outpatient Co., Ltd.

The total acquisition price for 51% equity in these companies is RMB 61.2 million.
On April 15, 2026, the board approved an adjustment to the payment arrangement for the equity transfer for two Changzhou-based companies. The relevant business registration for Liyang Jinboli Dental Outpatient and Liyang Licheng Jinboli Dental Outpatient has now been completed, and they have obtained new business licenses.

Business Registration Details

As of the disclosure date, all legal and business changes for the seven companies have been completed. However, the subsequent integration faces certain uncertainties, and the company will disclose relevant information in a timely manner.

Potential Impact on Investors & Stock Price Sensitivity

• The completion of this acquisition marks Shanghai Hile Bio’s expansion into the dental chain sector, which could enhance its competitiveness and profitability in medical health.
• The transaction involves a significant asset deployment (RMB 61.2 million), potentially impacting the company’s financial results and valuation.
• The completion of all registration processes demonstrates transaction certainty, and could boost investor confidence in the company’s transformation and expansion capabilities, with possible positive share price implications.
• However, investors should closely watch the integration process. If integration does not proceed smoothly, it could negatively impact performance and market sentiment.

Risk Warning

• Subsequent integration remains uncertain. The company will continue to disclose updates. Investors should pay attention to relevant risks.

Disclaimer: This article is an in-depth interpretation based on the company’s public disclosure and does not constitute any investment advice. Investors should make decisions based on their own circumstances and be aware of investment risks.

View *ST海利 Historical chart here